A comparative prospective open label randomized controlled 8 week study in patients of depression treated with vilazodone and sertraline
Keywords:Anxiety, Depression, Sertraline, Sexual dysfunction, Vilazodone
Background: Depression is a mood disorder treated with various antidepressant such as SSRIs due to lesser toxicity and improved safety profile.
Methods: This was an eight week randomised active controlled parallel group study. 54 patients were allocated in two group. Group A received vilazodone while group B received sertraline. Assessment done at baseline, 2, 4 and 8 weeks on the basis of clinical efficacy, sexual dysfunction, side effects and weight gain using Hamilton Depression Rating Scale (HAM-D), Hamilton Anxiety Rating Scale (HAM-A), Arizona Sexual Experience Scale (ASEX) and UKU Side Effect Rating Scale.
Results: HAM-D score of group A was 18.78±1.78 and 7.67±1.66 while in group B was 19.04±2.12 and 8.15±1.77 at baseline and 8 weeks respectively. HAM-A score of group A was 15.44±1.50 and 6.63±1.39 while in group B was 15.26±1.83 and 7.07±1.14 at baseline and 8 weeks. ASEX total score of group A was 15.63±1.28 and 14.63±1.33 while group B was 15.52±1.37 and 16.41±1.12 at baseline and 8 weeks. ASEX desire score of group A was 9.63±0.93 and 8.67±0.88 while of group B was 9.59±0.93 and 10.07±0.92 at baseline and 8 weeks. UKU side effect rating at 2 and 8 weeks of group A was 0.22±0.42, 1.04±0.76 while in group B was 0.37±0.49, 1.89±0.85.Conclusions: Vilazodone and Sertraline are equally efficacious in treatment of depression and associated anxiety. When side effect profile were compared Vilazodone is found superior to Sertraline
Sadock BJ, Sadock VA, Ruiz P. Kaplan and Sadock’s Comprehensive textbook of Psychiatry. 10th ed. Philadelphia: Lippincott Williams and Wilkins and Wolter Kluwer Health; 2015: 4099-4406.
Brunton LL. Goodman and Gillman’s The Pharmacological Basis of Therapeutics. 13th ed. McGraw Hill Professional; 2018:267-276.
Clayton AH, Croft HA, Handiwala L. Antidepressants and sexual dysfunction: mechanisms and clinical implications. Postgrad Med. 2014 Mar 1;126(2):91-9.
McCormack PL. Vilazodone: a review in major depressive disorder in adults. Drugs. 2015 Nov 1;75(16):1915-23.
Viibryd (vilazodone hydrochloride): US prescribing information. 2015. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda. Accessed 8 Oct 2015.
Hamilton M. A rating scale for depression. J Neurol, Neurosurg, Psychiatr. 1960 Feb;23(1):56.
Hamilton M. The assessment of anxiety states by rating. Brit J Med Psychol. 1959 Mar;32(1):50-5.
A. McGahuey, Alan J. Gelenberg, Cindi A. Laukes, Francisco A. Moreno, Pedro L. Delgado, Kathy M. McKnight, et al. The Arizona sexual experience scale (ASEX): reliability and validity. J Sex Marital Ther. 2000 Jan 1;26(1):25-40.
Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Scandinavica. 1987;76(334):1-100.
Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Pae CU. Vilazodone for the treatment of major depressive disorder: focusing on its clinical studies and mechanism of action. Psychiatr Investiga. 2015 Apr;12(2):155.
Reed CR, Kajdasz DK, Whalen H, Athanasiou MC, Gallipoli S, Thase ME. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder. Curr Med Res Opinion. 2012 Jan 1;28(1):27-39.
Ambrosini PJ, Wagner KD, Biederman J, Glick I, Tan C, Elia J, et al. Multicenter open‐label sertraline study in adolescent outpatients with major depression. J Am Acad Child Adolescent Psychiatr. 1999 May 1;38(5):566-72.
Mowla A, Dastgheib SA, Jahromi LR. Comparing the effects of sertraline with duloxetine for depression severity and symptoms: a double-blind, randomized controlled trial. Clini Drug Investigation. 2016 Jul 1;36(7):539-43.
Croft HA, Pomara N, Gommoll C, Chen D, Nunez R, Mathews M. Efficacy and safety of vilazodone in major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Clini Psychiatr. 2014 Nov 24;75(11):1291-8.
Citrome L, Gommoll CP, Tang X, Nunez R, Mathews M. Evaluating the efficacy of vilazodone in achieving remission in patients with major depressive disorder: post-hoc analyses of a phase IV trial. Inter Clini Psychopharmacol. 2015 Mar;30(2):75.
Allgulander C, Dahl AA, Austin C, Morris PL, Sogaard JA, Fayyad R, et al. Efficacy of sertraline in a 12-week trial for generalized anxiety disorder. Am J Psychiatr. 2004 Sep 1;161(9):1642-9.
Bathla M, Anjum S, Singh M, Panchal S, Singh GP. A 12-week comparative prospective open-label randomized controlled study in depression patients treated with vilazodone and escitalopram in a tertiary care hospital in North India. Ind J Psychol Med. 2018 Jan;40(1):80.
Talas A, Cerit C, Akpınar Aslan E. Comparison of the effects of sertraline and agomelatine on sleep quality, sexual functioning and metabolic parameters in patients with major depressive disorder. Psychiatr Clini Psychopharmacol. 2019 Jul 3;29(3):257-63.
Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clini Psychopharmacol. 2009 Jun 1;29(3):259-66.
Gommoll C, Durgam S, Mathews M, Forero G, Nunez R, Tang X, et al. A double‐blind, randomized, placebo‐controlled, fixed‐dose phase III study of vilazodone in patients with generalized anxiety disorder. Depression Anxiety. 2015 Jun;32(6):451-9.